Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1113 participants.

Also called NCT05772169

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,113 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05772169
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05772169. Randomized; triple masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-11-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Condition
Hypercortisolism
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Mifepristone 300 MG [Korlym]
Intervention (Drug)
Placebo for mifepristone
Lead sponsor
Corcept Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct05772169
Content hash
a2db7d54feec9289af5ec03bc5d57d6c0b87187847f2dd73512b19891b7de6f4